Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
15.51
+0.20 (1.31%)
At close: Aug 1, 2025, 4:00 PM
15.54
+0.03 (0.19%)
After-hours: Aug 1, 2025, 4:10 PM EDT
Company Description
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders.
Its product candidate includes verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, as well as in Phase I clinical trial for treating chronic obstructive pulmonary disease.
The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Upstream Bio, Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Oct 11, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 52 |
| CEO | E. Sutherland |
Contact Details
Address: 890 Winter Street, Suite 200 Waltham, Massachusetts 02451 United States | |
| Phone | 781 208 2466 |
| Website | upstreambio.com |
Stock Details
| Ticker Symbol | UPB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0002022626 |
| ISIN Number | US91678A1079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. E. Rand Sutherland M.D., M.P.H., MPH | Chief Executive Officer and Director |
| Michael Paul Gray CPA, MBA | Chief Financial Officer and Chief Operating Officer |
| Allison C. Ambrose J.D. | Senior Vice President, General Counsel and Secretary |
| Stacy Price M.S., P.M.P. | Chief Technology Officer |
| Lisa Fiering | Senior Vice President of People and Culture |
| Dr. Adam Houghton M.B.A., Ph.D. | Chief Business Officer |
| Aaron Deykin M.D. | Chief Medical Officer and Head of Research and Development |
| Mersedeh Miraliakbari Pharm.D. | Senior Vice President of Regulatory Affairs and Quality |
| Fang Xie Ph.D. | Vice President and Head of Biometrics |
| Dr. Sumathi Sivapalasingam M.D. | Vice President and Head of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 12, 2025 | 8-K | Current Report |
| May 6, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 17, 2025 | ARS | Filing |
| Apr 17, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 12, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 12, 2025 | 10-K | Annual Report |
| Mar 12, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |